Hunterdon Hematology Oncology

What Hunterdon Hematology Oncology does

Hunterdon Hematology Oncology (HHO) is a privately held, physician-owned community oncology and hematology practice operating as an LLC out of Flemington, New Jersey, founded in 1990 and serving patients across Hunterdon, Warren, Somerset, and Mercer counties in Central New Jersey. The practice employs five board-certified hematologist-oncologists — Dr. Myron Bednar, Dr. Megha Shah, Dr. Swee Jian Ngeow, Dr. Waqas Rehman, and Dr. Kevin Wang — and six PA-Cs, operating from three locations: the main infusion center at 2100 Wescott Drive inside the Hunterdon Regional Cancer Center (HRCC), a second Flemington suite in the Doctor's Building at 1100 Wescott Drive, and a Hawk Pointe satellite in Washington, NJ. HHO is accredited by the American College of Surgeons' Commission on Cancer and by ACHC, distinctions held by roughly one in four cancer facilities nationally.

The practice delivers a full-service medical oncology and hematology portfolio spanning chemotherapy, immunotherapy (including certified PROVENGE/sipuleucel-T administration for advanced prostate cancer), personalized targeted therapy guided by next-generation sequencing and genetic tumor profiling, supportive care including the Paxman FDA-cleared scalp cooling system, and integrative oncology services (dietary, behavioral counseling, palliative care coordination). Differentiated clinical research is delivered through an ongoing partnership with Fox Chase Cancer Center, providing community access to National Cooperative Group trials such as GO42784, ASCENT-05, Briacell, BGB-A317-316, TAILOR, Biovica Divitum, and ULI-EAP-100, with Dr. Bednar serving as advisor to Fox Chase's extramural research program.

HHO's revenue model is fee-for-service medical practice billing through commercial insurance, Medicare, and Medicaid, supplemented by pharmaceutical-sponsored clinical trial income. Go-to-market is sales-led via referrals from Hunterdon Health Network primary care physicians and regional specialists, supported by direct patient intake through the HHO website, online appointment booking, and word-of-mouth. Operating infrastructure runs on NextGen Healthcare and MedFusion patient portals with InstaMed payment processing. The practice is privately held by its five physician partners with no PE, VC, or parent-company ownership disclosed.

Name

Hunterdon Hematology Oncology

Legal name

Hunterdon Hematology Oncology, LLC

Website

https://hhocancer.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

11–50 employees

Short description

Hunterdon Hematology Oncology is a physician-owned community oncology and hematology practice in Flemington, NJ, delivering chemotherapy, immunotherapy, targeted therapy, clinical trials, and supportive care to cancer and blood-disorder patients across Central New Jersey.

Ownership category

akta.pro rank

Product category

Oncology and Hematology Medical Services

NAICS

Offices of Physicians (62111), Medical and Diagnostic Laboratories (62151)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Hematology (Benign Hematology) (HLAKAFAA), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Community oncology services
• Hematology cancer treatment
• Chemotherapy infusion therapy
• Oncology clinical trials
• Personalized targeted therapy

Headquarters

HQ city

Flemington

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Medical Oncology Services: Billable medical services including consultations, chemotherapy infusions, immunotherapy treatments, and ongoing cancer care management billed through insurance plans and Medicare/Medicaid
2. Clinical Trial Research: Participation in clinical trials with pharmaceutical company sponsorship and National Cancer Institute cooperative group research funding

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Hunterdon Hematology Oncology provides community-based medical oncology and hematology services, including cancer diagnosis, chemotherapy administration, immunotherapy, personalized targeted therapy, and access to clinical trials. The practice operates an on-site infusion center and is co-located within the Hunterdon Regional Cancer Center, offering patients integrated access to surgical, radiation, and supportive oncology services across three New Jersey locations.

Product overview

Hunterdon Hematology Oncology is a community oncology group providing comprehensive cancer and blood disorder treatment services from its facilities in Flemington, New Jersey. The practice offers a unified portfolio of core treatment services including chemotherapy, immunotherapy, and personalized targeted therapy, supplemented by access to clinical trials through a partnership with Fox Chase Cancer Center. Supportive care is delivered through integrative oncology combining traditional medicine with complementary therapies, and the Paxman Scalp Cooling System for hair loss prevention during chemotherapy. The practice is uniquely positioned within the Hunterdon Regional Cancer Center, providing access to additional specialists, radiation oncology, physical therapy, genetic counseling, and laboratory and pharmacy services in one location.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Hair loss reduction: 50.5% of scalp cooling patients had less than 50% hair loss vs 0% without cooling

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Hunterdon Regional Cancer Center (HRCC)coreStrategic or Co-development PartnerHHO is uniquely positioned within the comprehensive Hunterdon Regional Cancer Center. This affiliation allows patients access to surgeons, radiation oncology, physical therapy, genetic counseling, and other supportive services in one location. The practice maintains its main office and infusion center within HRCC facilities.
• Fox Chase Cancer CentercoreStrategic or Co-development PartnerPartnership enables HHO to participate in Fox Chase Cancer Center clinical trials, allowing patients to receive cutting-edge treatments close to home rather than traveling to Philadelphia. Dr. Bednar serves as advisor for Fox Chase's extramural research program. The practice also maintains affiliation for clinical trial referrals and research collaboration.
• National Cooperative Groups ProgramminorStrategic or Co-development PartnerDr. Bednar and Hunterdon Regional Cancer Center participate in research trials through the National Cooperative Groups Program, which coordinates multi-center clinical trials across institutions.
• Hunterdon Medical CentercoreStrategic or Co-development PartnerIntegration with Hunterdon Medical Center for hospital-based services, surgery coordination, palliative care referrals, and comprehensive cancer program accreditation through Commission on Cancer.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Memorial Sloan Kettering Cancer Center: Premier academic oncology center. While not a direct community competitor, MSK's regional care network competes for Central NJ patients willing to travel and serves as the upper-tier benchmark against which HHO's 'academic-level care close to home' positioning is measured.
• RWJBarnabas Health Oncology: Large NJ health system offering comprehensive oncology services including infusion, radiation, and clinical trials across multiple hospitals. Competes for the same Central NJ patient pool as HHO with broader service lines and hospital infrastructure.
• Fox Chase Cancer Center: NCI-designated Comprehensive Cancer Center and HHO's primary clinical trials partner. Comparable in oncology treatment offerings and physician training pedigree, but operates as an academic medical center rather than a community practice, with hospital-based and research-driven economics.
• Hackensack Meridian Health Cancer Care: Major NJ health system with multiple cancer centers offering medical oncology, infusion, and clinical trials. Competes with HHO for oncology patients in the northern and central NJ corridor with greater scale and broader service portfolio.

Others

• Hunterdon Medical Center: HHO's primary hospital partner and host facility within Hunterdon Regional Cancer Center. While not a direct oncology competitor, it provides the integrated infrastructure (surgery, radiation, ER, palliative care) that HHO's model depends on, making it a critical ecosystem participant.

Emerging players

• OneOncology: PE-backed platform aggregating independent community oncology practices nationwide. A potential acquirer or competitor to HHO; its growth trajectory signals where independent practices like HHO are likely to be pressured or consolidated.
• The US Oncology Network: Nation's largest network of community oncology practices, supported by McKesson. While not a single practice peer, US Oncology's affiliated practices represent HHO's most significant competitive and partnership model — many independent community oncology groups have joined or sold to this network.

Direct peers

• ASTERA Cancer Care: Large New Jersey-based community oncology practice offering medical oncology, hematology, and infusion services across multiple NJ locations. Directly comparable to HHO in specialty and geography, but at significantly greater scale with a broader physician roster.
• Regional Cancer Care Associates (RCCA): Multi-site community oncology practice serving New Jersey, Connecticut, and Maryland. Comparable to HHO in offering chemotherapy, immunotherapy, clinical trials, and supportive care in community settings, but with substantially greater geographic reach and scale.
• New Jersey Cancer Care: Community-based hematology/oncology practice in New Jersey offering chemotherapy, immunotherapy, and infusion services. Closely mirrors HHO's service model in the same regional market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hunterdon Hematology Oncology